TSHA

Taysha Gene Therapies, Inc.

A clinical-stage biotech developing gene therapies for rare nervous-system diseases. Founded in 2019 out of the University of Texas Southwestern Medical Center in Dallas, its lead program TSHA-102 is designed to treat the genetic root cause of Rett syndrome by delivering a single MECP2 gene directly into the spinal fluid. The company takes its name from the Caddo word "taysha," meaning "friend" or "ally" — the same word that gave Texas its name.

CUSIP: 877619106HealthcareUS1 holder

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last year

Nolan Sean P.Chief Executive Officer, Director · 3 transactions

4.44M+23%

Granted 1.01M · Sold 178.1K

Stalfort John A IIIDirector · 1 transaction

2.06M+1%

Granted 21.3K

Alam KamranCHIEF FINANCIAL OFFICER · 4 transactions

1.44M+21.4%

Granted 359.0K · Sold 104.5K

Nagendran SukumarPresident and Head of R&D, Director · 15 transactions

1.34M+14.7%

Granted 1.06M · Sold 1.09M

Donenberg Phillip B.Director · 1 transaction

241.3K+9.7%

Granted 21.3K

Long Alison SDirector · 1 transaction

127.2K+20.2%

Granted 21.3K

Sepp-Lorenzino LauraDirector · 1 transaction

127.2K+20.2%

Granted 21.3K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Nolan Sean P.Chief Executive Officer, Director · 3 transactions	+23%	4.44M	1.01M	—	178.1K
Stalfort John A IIIDirector · 1 transaction	+1%	2.06M	21.3K	—	—
Alam KamranCHIEF FINANCIAL OFFICER · 4 transactions	+21.4%	1.44M	359.0K	—	104.5K
Nagendran SukumarPresident and Head of R&D, Director · 15 transactions	+14.7%	1.34M	1.06M	—	1.09M
Donenberg Phillip B.Director · 1 transaction	+9.7%	241.3K	21.3K	—	—
Long Alison SDirector · 1 transaction	+20.2%	127.2K	21.3K	—	—
Sepp-Lorenzino LauraDirector · 1 transaction	+20.2%	127.2K	21.3K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.